Immuneering Study update
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Welcome to the Immuneering conference call to discuss its expanded development strategy, including two new clinical collaborations with Astellas in pancreatic cancer and new company-sponsored clinical program in thyroid cancer. At this time, all participants are in listen-only mode. Following the management's prepared remarks, we will hold the Q&A session. To ensure that we have ample time to address everyone's questions, we would ask each person to limit themselves to one question and one follow-up. As a reminder, this call is being recorded today, Thursday, November 12, 2026. I would now like to turn the conference call over to Laurence Watts of the New Street Investor Relations. Please go ahead. Thank you, operator.
Joining us on the call today from Immuneering are Co-founder and Chief Executive Officer Ben Zeskind, Chief Scientific Officer Brett Hall, Chief Medical Officer Igor Matushansky, and Chief Financial Officer Andrew Gengos. In addition, we are delighted to have on the call Dr. Alan Ho, Chief of the Head and Neck Oncology Service at Memorial Sloan Kettering Cancer Center. During this call, management will make forward-looking statements, including statements related to its clinical development plans for atebimetinib, as well as the timing of data from its own and partnered clinical development studies. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties.
Factors that could cause these results to be different from these statements include factors the company describes in its securities filings, including its annual report on Form 10-K and our quarterly reports on Form 10-Q. Immuneering undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events, or changes in its expectations. With that, I would like to turn the call over to Ben Zeskind, Chief Executive Officer of Immuneering.
Ben? Thank you, Laurence, and thank you to everyone joining us today.
Today is an important day in what has already been a transformative year for Immuneering and the cancer patients we serve. At ASCO in June, we reported 17.3 months median overall survival in our ongoing phase II study in first-line pancreatic cancer, with what we believe is a potentially best-in-class tolerability profile and 84% of evaluable patients weight stable or gaining weight at three months. This was an all-comers population with no genetic testing required. These data support our aspiration to deliver long survival with outstanding quality of life in a broad population of patients. We recently announced that this trial is being extended as patients are living longer than projected on atebimetinib, and we plan to share another update in the first half of 2027.
Building on this momentum, we began dosing patients in MAPKeeper 301, our phase III registrational trial in pancreatic cancer, which is enrolling rapidly ahead of schedule and generating substantial excitement in the oncology community. With the phase III going so well, now is the time to embark on an expanded program of development, which we believe greatly increases the opportunity to create value for patients and shareholders. Today, we are announcing three important new clinical trials that illustrate the significant breadth of atebimetinib's potential. We are thrilled to be starting two new trials in collaboration with and sponsored by Astellas that will evaluate two distinct CLDN18.2-directed approaches in combination with atebimetinib in pancreatic cancer. We are also excited to announce a new phase II trial of atebimetinib in combination with chemotherapy in anaplastic thyroid cancer, or ATC. I am particularly pleased that Dr. Ho is able to join us.
His experience treating patients with anaplastic thyroid cancer will bring an important clinical perspective to our discussion. These three new trials are in addition to the phase II trial of atebimetinib in combination with Regeneron's anti-PD-1 cemiplimab, for which we expect to dose the first patient by the end of the year. Four distinct combinations in different settings with a simple unifying idea: atebimetinib has the potential to deliver long survival and outstanding quality of life to a wide set of cancer patients, and to make it possible to combine MAP kinase pathway inhibition with a broad range of other cancer treatments. Today, we will begin with the scientific and strategic foundation for our pipeline expansion, then discuss the Astellas collaborations, then turn to the thyroid cancer opportunity, including hearing from Dr. Ho. We will then open the call for questions.
As a reminder, our lead program, atebimetinib, is an oral, once-daily third-generation MEK inhibitor. We designed it to address the limitations of earlier-generation MEK inhibitors, including tolerability and resistance, while preserving the potential body mass benefits associated with MEK inhibition. The key preclinical data was recently published in Cancer Research and highlighted in a spotlight commentary. We chose the MAP kinase pathway for our first program because it plays a central role in so many solid tumors. MEK is a critical signaling node downstream of RAS and RAF, and a compelling target if you can inhibit it in a way that patients can tolerate over time. Conventional continuous inhibition can put sustained pressure on both tumor cells and healthy tissues. That pressure can contribute to toxicity and the emergence of resistance. Our Deep Cyclic Inhibition approach is different.
It is designed to deliver deep, transient pathway inhibition, followed by a recovery window. We believe that this approach may allow us to disrupt tumor signaling while limiting some of the trade-offs of chronic inhibition. There is a second strategic benefit. If atebimetinib can be combined effectively with other therapies, it can become a backbone on which to build combination regimens. We see at least six broad categories of opportunity with preclinical data that support and enable all of them. Combinations with chemotherapy are the furthest along clinically, and combinations with immunotherapies will be starting shortly in lung cancer. We chose these three new studies with an eye towards combinations that can produce fast paths to data in a capital-efficient way. The Astellas collaboration we are announcing today will explore additional targeted and immune-engaging approaches in pancreatic cancer.
Our planned ATC program extends the chemotherapy combination strategy into a different and particularly aggressive tumor type. Altogether, this is the beginning of a much more expansive clinical development strategy. With that background, let me now turn to today's first announcement, our clinical trial collaboration and supply agreement with Astellas Pharma Global Development, a subsidiary of Astellas Pharma Inc. Under this agreement, Astellas will sponsor and conduct two planned clinical studies in pancreatic cancer patients whose tumors express Claudin 18.2. Immuneering will provide atebimetinib for both studies, and the companies will each retain global development and commercialization rights for their respective investigational medicines. The first planned study will evaluate an investigational Claudin 18.2-targeted Astellas candidate added to atebimetinib, plus modified gemcitabine and nab-paclitaxel in first-line metastatic pancreatic cancer.
In other words, it builds on the chemotherapy backbone that we are already studying with atebimetinib while adding a further targeted treatment modality. The second planned study is especially interesting because it will evaluate a chemotherapy-free regimen, combining atebimetinib with a different investigational Claudin 18.2-targeted Astellas program. That study is expected to include previously treated patients with metastatic pancreatic cancer. These are distinct approaches, and we should not assume that they will behave the same way clinically, which is precisely why we are excited to evaluate them. We want to learn whether the characteristics of atebimetinib can support a broad range of combinations for different patient populations. We expect to share additional study details when appropriate and in coordination with our collaborator.
Importantly, we believe this agreement is a huge vote of confidence in atebimetinib and a capital-efficient way for Immuneering to demonstrate atebimetinib's potential as a backbone treatment, thanks to its highly differentiated safety and tolerability profile. Claudin 18.2 is an emerging target in gastrointestinal oncology, including about 30% of pancreatic tumors. Its expression creates an opportunity to direct investigational therapies towards tumor cells using mechanisms distinct from MEK inhibition. For us, the strategic point is not that one combination is necessarily superior to another. It is that atebimetinib could be a flexible partner for multiple therapeutic modalities. One approach adds a Claudin 18.2-directed therapy to our existing atebimetinib and chemotherapy regimen. The other explores whether a Claudin 18.2-directed treatment can be paired with atebimetinib without chemotherapy. These studies will help us understand whether combining complementary mechanisms can improve outcomes in patients with Claudin 18.2-expressing pancreatic cancer.
We view this collaboration as further validation of the scientific interest in atebimetinib as a combination partner and as an efficient way to explore additional opportunities alongside our internally sponsored programs. Other similar discussions are ongoing, so this may be just the beginning. Now, I would like to turn to our second announcement, which takes us into a different type of cancer, anaplastic thyroid cancer, or ATC. ATC is rare, but it is one of the most aggressive cancers physicians encounter. Tumors can grow extraordinarily quickly, and patients often present with locally advanced or metastatic disease. Although targeted therapies have improved outcomes for certain molecularly defined groups, many patients still have limited options. The MAP kinase pathway is implicated in ATC, including through alterations involving BRAF and RAS, which we believe creates a strong biological rationale for studying atebimetinib in this setting, particularly in combination with chemotherapy.
In addition, the number of patients required for this planned trial is small, making it capital-efficient and enabling a fast path to a potentially registrational readout. Today, we are announcing plans for a phase II clinical study of atebimetinib plus chemotherapy in ATC. We plan to submit an IND to the FDA by the end of this year and, subject to regulatory clearance, target dosing our first patients in mid-2027. Our scientific rationale will be featured in a preclinical poster at the EORTC-NCI-AACR Symposium in Barcelona on November 18. That presentation is entitled "Atebimetinib, a Deep Cyclic Inhibitor of MEK, Combined with Chemotherapy: Preclinical Rationale for Treatment of Anaplastic Thyroid Cancer." It is abstract 144, poster PB144. We look forward to sharing those data at the meeting, and I will not preempt the scientific presentation today.
To help explain why this disease is such an important opportunity, I would now like to invite Dr. Alan Ho to share his perspective.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
10 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
